18742449. TREATMENT OF CANCER USING A HLA-A2/MAGE-A4 X CD3 BISPECIFIC ANTIBODY AND A 4-1BB (CD137) AGONIST simplified abstract (Hoffmann-La Roche Inc.)

TREATMENT OF CANCER USING A HLA-A2/MAGE-A4 X CD3 BISPECIFIC ANTIBODY AND A 4-1BB (CD137) AGONIST

Organization Name

Hoffmann-La Roche Inc.

Inventor(s)

Simon Patrick Keiser of Aarau (CH)

Tina Weinzierl of Eggenwil (CH)

TREATMENT OF CANCER USING A HLA-A2/MAGE-A4 X CD3 BISPECIFIC ANTIBODY AND A 4-1BB (CD137) AGONIST - A simplified explanation of the abstract

This abstract first appeared for US patent application 18742449 titled 'TREATMENT OF CANCER USING A HLA-A2/MAGE-A4 X CD3 BISPECIFIC ANTIBODY AND A 4-1BB (CD137) AGONIST

The present invention involves the treatment of cancer using a HLA-A2/MAGE-A4×CD3 bispecific antibody and a 4-1BB (CD137) agonist.

• This patent application focuses on a novel approach to treating cancer by targeting specific antigens with bispecific antibodies.
• The combination of the HLA-A2/MAGE-A4×CD3 bispecific antibody and the 4-1BB agonist aims to enhance the immune response against cancer cells.
• By activating the CD3 and CD137 pathways, this treatment strategy may lead to improved anti-tumor activity.
• The innovation lies in the unique combination of these two components to target cancer cells more effectively.
• This approach has the potential to revolutionize cancer treatment by harnessing the power of the immune system to fight against tumors.

Potential Applications: - Treatment of various types of cancer - Immunotherapy for patients with HLA-A2/MAGE-A4-positive tumors - Combination therapy with existing cancer treatments

Problems Solved: - Enhancing the immune response against cancer cells - Targeting specific antigens for more precise treatment - Improving anti-tumor activity

Benefits: - Increased efficacy in cancer treatment - Reduced side effects compared to traditional therapies - Potential for personalized medicine based on antigen expression

Commercial Applications: Title: Innovative Cancer Treatment Using Bispecific Antibody and CD137 Agonist This technology has the potential to be used in pharmaceutical companies developing cancer therapies, biotech firms focusing on immunotherapy, and research institutions studying novel cancer treatments.

Questions about the technology: 1. How does the combination of the bispecific antibody and CD137 agonist enhance the immune response against cancer cells? 2. What types of cancer are most likely to benefit from this treatment approach?

Original Abstract Submitted

The present invention relates to the treatment of cancer, in particular to the treatment of cancer using a HLA-A2/MAGE-A4×CD3 bispecific antibody and a 4-1BB (CD137) agonist.